Outsourcing in Clinical Trials West Coast 2023
San Francisco, CA
March 1-2, 2023
San Francisco, CA
March 1-2, 2023
April 26-28, 2023
October 4-6, 2023
Safety, efficiency, quality, endurance, and speed. These are the qualities needed for winning an Olympic medal, and what you should and can expect from active protocol compliance management. Through a dialogue of industry trends and real-world experiences, learn ways to reduce key risks to study startup and site performance in the context of site-based and hybrid trials, and recognize how significant study-related education is to improving compliance.
There has been a dramatic shift in the ways investigators and site staff must conduct their clinical trial operations since the COVID-19 pandemic. The drug development industry was quickly forced to adopt new, alternative solutions. However, the need for innovative transformations of sponsor's clinical operations began long before the pandemic. In this webinar, we discuss the overwhelming need for flexible innovation amongst site initiation visits (SIVs) and investigator meetings (IMs). Our panelists discuss the challenges and benefits of both SIVs and IMs and how the overall challenges continue to grow as virtual meetings become more widely used.
Since the beginning of the COVID-19 pandemic the FDA has urged agencies around the world to modernize their clinical trials by using disruptive technology and decentralized training approaches. With more than half of ongoing trials being delayed due to the pandemic, the need for virtualization of clinical trials has risen dramatically. By prioritizing remote trial technology, sponsors can improve patient recruitment and lower operating costs of their trials. In this Q&A, we discuss the trends of training content in virtual settings, the challenges and benefits of those implemented IM and SIV training approaches, and the need for ongoing training during the course of the study.
As COVID-19 unmanageably accelerates, so does the rate of disruption for clinical trial operations and the risk of increased protocol deviations. Drug development executives continue to be plagued with finding new means of sustaining site engagement, enhancing site training, and maintaining data quality throughout the life cycle of the trial. Methods must be employed to avoid communicative breakdowns between the site and the sponsor and elevate this partnership amidst COVID-inflicted restrictions. In this webinar, we engage in thorough discussions on optimizing and revolutionizing trial models to meet timelines and create cohesiveness amongst all players: the site, the sponsor, the CRO and the investigator.
Clinical trials have adapted quickly to the virtual world by necessity and clinical teams are experimenting with new methods of virtual meetings, remote training, and study start up. In this webinar we review and examine the success and pitfalls of remote training solutions and global access to digital resources, as well as proven methods to increase attention & engagement for virtual teams. Learn from experienced pharmaceutical leaders on how solutions can be optimized for remote trials and how their lessons can improve all Investigator Meetings (IMs), Site Initiation Visits (SIVs), and clinical training.